FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003877973> ?p ?o ?g. }

• W2003877973 endingPage "356" @default.
• W2003877973 startingPage "348" @default.
• W2003877973 abstract "Sepsis causes more than with 215,000 deaths per year in the United States alone. Death can be caused by multiple system organ failure, with the lung, in the form of the acute respiratory distress syndrome (ARDS), often being the first organ to fail. We developed a chronic porcine model of septic shock and ARDS and hypothesized that blocking the proteases neutrophil elastase (NE) and matrix metalloproteinases (MMP-2 and MMP-9) with the modified tetracycline, COL-3, would significantly improve morbidity in this model. Pigs were anesthetized and instrumented for hemodynamic monitoring and were then randomized to one of three groups: control (n = 3), laparotomy only; superior mesenteric artery occlusion (SMA) + fecal blood clot (FC; n = 7), with intraperitoneal placement of a FC; and SMA + FC + COL (n = 5), ingestion of COL-3 12 h before injury. Animals emerged from anesthesia and were monitored and treated with fluids and antibiotics in an animal intensive care unit continuously for 48 h. Serum and bronchoalveolar lavage fluid (BALF) were sampled and bacterial cultures, MMP-2, MMP-9, NE, and multiple cytokine concentrations were measured. Pigs were reanesthetized and placed on a ventilator when significant lung impairment occurred (PaO2/FiO2 < 250). At necropsy, lung water and histology were assessed. All animals in the SMA + FC group developed septic shock evidenced by a significant fall in arterial blood pressure that was not responsive to fluids. Lung injury typical of ARDS (i.e., a fall in lung compliance and PaO2/FiO2 ratio and a significant increase in lung water) developed in this group. Additionally, there was a significant increase in plasma IL-1 and IL-6 and in BALF IL-6, IL-8, IL-10, NE, and protein concentration in the SMA + FC group. COL-3 treatment prevented septic shock and ARDS and significantly decreased cytokine levels in plasma and BALF. COL-3 treatment also significantly reduced NE activity (P < 0.05) and reduced MMP-2 and MMP-9 activity in BALF by 64% and 34%, respectively, compared with the SMA + FC group. We conclude that prophylactic COL-3 prevented the development of ARDS and unexpectedly also prevented septic shock in a chronic insidious onset animal model of sepsis-induced ARDS. The mechanism of this protection is unclear, as COL-3 inhibited numerous inflammatory mediators. Nevertheless, COL-3 significantly reduced the morbidity in a clinically applicable animal model, demonstrating the possibility that COL-3 may be useful in reducing the morbidity associated with sepsis and ischemia/reperfusion injury in patients." @default.
• W2003877973 created "2016-06-24" @default.
• W2003877973 creator A5011575122 @default.
• W2003877973 creator A5020282683 @default.
• W2003877973 creator A5028541932 @default.
• W2003877973 creator A5063288267 @default.
• W2003877973 creator A5065550494 @default.
• W2003877973 creator A5089481130 @default.
• W2003877973 creator A5090326441 @default.
• W2003877973 creator A5091815057 @default.
• W2003877973 date "2005-10-01" @default.
• W2003877973 modified "2023-10-16" @default.
• W2003877973 title "CHEMICALLY MODIFIED TETRACYCLINE PREVENTS THE DEVELOPMENT OF SEPTIC SHOCK AND ACUTE RESPIRATORY DISTRESS SYNDROME IN A CLINICALLY APPLICABLE PORCINE MODEL" @default.
• W2003877973 cites W1595045823 @default.
• W2003877973 cites W1823110768 @default.
• W2003877973 cites W1966160772 @default.
• W2003877973 cites W1981278668 @default.
• W2003877973 cites W1995140501 @default.
• W2003877973 cites W2002257788 @default.
• W2003877973 cites W2016134303 @default.
• W2003877973 cites W2019043807 @default.
• W2003877973 cites W2021275551 @default.
• W2003877973 cites W2029584932 @default.
• W2003877973 cites W2049927822 @default.
• W2003877973 cites W2052900652 @default.
• W2003877973 cites W2056482472 @default.
• W2003877973 cites W2064013566 @default.
• W2003877973 cites W2064107559 @default.
• W2003877973 cites W2070824863 @default.
• W2003877973 cites W2079608251 @default.
• W2003877973 cites W2087169937 @default.
• W2003877973 cites W2087765734 @default.
• W2003877973 cites W2090069553 @default.
• W2003877973 cites W2095258584 @default.
• W2003877973 cites W2102404503 @default.
• W2003877973 cites W2111322974 @default.
• W2003877973 cites W2124552117 @default.
• W2003877973 cites W2145577370 @default.
• W2003877973 cites W2157767878 @default.
• W2003877973 cites W2161328469 @default.
• W2003877973 cites W2167065590 @default.
• W2003877973 cites W2317980238 @default.
• W2003877973 cites W2318149275 @default.
• W2003877973 cites W2341811425 @default.
• W2003877973 doi "https://doi.org/10.1097/01.shk.0000180619.06317.2c" @default.
• W2003877973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16205320" @default.
• W2003877973 hasPublicationYear "2005" @default.
• W2003877973 type Work @default.
• W2003877973 sameAs 2003877973 @default.
• W2003877973 citedByCount "82" @default.
• W2003877973 countsByYear W20038779732012 @default.
• W2003877973 countsByYear W20038779732013 @default.
• W2003877973 countsByYear W20038779732014 @default.
• W2003877973 countsByYear W20038779732015 @default.
• W2003877973 countsByYear W20038779732016 @default.
• W2003877973 countsByYear W20038779732017 @default.
• W2003877973 countsByYear W20038779732018 @default.
• W2003877973 countsByYear W20038779732019 @default.
• W2003877973 countsByYear W20038779732020 @default.
• W2003877973 countsByYear W20038779732021 @default.
• W2003877973 countsByYear W20038779732022 @default.
• W2003877973 countsByYear W20038779732023 @default.
• W2003877973 crossrefType "journal-article" @default.
• W2003877973 hasAuthorship W2003877973A5011575122 @default.
• W2003877973 hasAuthorship W2003877973A5020282683 @default.
• W2003877973 hasAuthorship W2003877973A5028541932 @default.
• W2003877973 hasAuthorship W2003877973A5063288267 @default.
• W2003877973 hasAuthorship W2003877973A5065550494 @default.
• W2003877973 hasAuthorship W2003877973A5089481130 @default.
• W2003877973 hasAuthorship W2003877973A5090326441 @default.
• W2003877973 hasAuthorship W2003877973A5091815057 @default.
• W2003877973 hasBestOaLocation W20038779731 @default.
• W2003877973 hasConcept C126322002 @default.
• W2003877973 hasConcept C141071460 @default.
• W2003877973 hasConcept C141983124 @default.
• W2003877973 hasConcept C2776348555 @default.
• W2003877973 hasConcept C2777628635 @default.
• W2003877973 hasConcept C2777714996 @default.
• W2003877973 hasConcept C2777961210 @default.
• W2003877973 hasConcept C2778384902 @default.
• W2003877973 hasConcept C2781046184 @default.
• W2003877973 hasConcept C2781300812 @default.
• W2003877973 hasConcept C2909621147 @default.
• W2003877973 hasConcept C42219234 @default.
• W2003877973 hasConcept C71924100 @default.
• W2003877973 hasConcept C9418649 @default.
• W2003877973 hasConceptScore W2003877973C126322002 @default.
• W2003877973 hasConceptScore W2003877973C141071460 @default.
• W2003877973 hasConceptScore W2003877973C141983124 @default.
• W2003877973 hasConceptScore W2003877973C2776348555 @default.
• W2003877973 hasConceptScore W2003877973C2777628635 @default.
• W2003877973 hasConceptScore W2003877973C2777714996 @default.
• W2003877973 hasConceptScore W2003877973C2777961210 @default.
• W2003877973 hasConceptScore W2003877973C2778384902 @default.
• W2003877973 hasConceptScore W2003877973C2781046184 @default.
• W2003877973 hasConceptScore W2003877973C2781300812 @default.
• W2003877973 hasConceptScore W2003877973C2909621147 @default.
• W2003877973 hasConceptScore W2003877973C42219234 @default.

• next